Latanoprost

Key facts

Invented name
Xalatan
Active substance
Latanoprost
Therapeutic area
Ophthalmology
Decision number
P/220/2009
PIP number
Latanoprost
Pharmaceutical form(s)
Eye drops, solution
Condition(s) / indication(s)
Treatment of glaucoma
Route(s) of administration
Ocular use
Contact for public enquiries
Pfizer Global Research & Development
E-mail: PIP_Enquiries@pfizer.com
Country: United Kingdom
Phone: +44 13046446607
Fax: +44 1304646607 
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000011-PIP01-07-M03
Compliance opinion date
19/03/2010
Compliance outcome
positive

Topics

How useful was this page?

Add your rating